Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Population pharmacokinetics of abacavir in pregnant women.

Literature DB >> 25070097

Population pharmacokinetics of abacavir in pregnant women.

Floris Fauchet¹, Jean-Marc Treluyer², Laure-Helene Préta³, Elodie Valade⁴, Emmanuelle Pannier⁵, Saik Urien⁶, Déborah Hirt².

Abstract

For the first time, a population approach was used to describe abacavir (ABC) pharmacokinetics in HIV-infected pregnant and nonpregnant women. A total of 266 samples from 150 women were obtained. No covariate effect (from age, body weight, pregnancy, or gestational age) on ABC pharmacokinetics was found. Thus, it seems unnecessary to adapt the ABC dosing regimen during pregnancy.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2014 PMID： 25070097 PMCID： PMC4187964 DOI： 10.1128/AAC.03469-14

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

15 in total

1. Ways to fit a PK model with some data below the quantification limit.

Authors: S L Beal
Journal: J Pharmacokinet Pharmacodyn Date: 2001-10 Impact factor: 2.745

2. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.

Authors: S Staszewski; P Keiser; J Montaner; F Raffi; J Gathe; V Brotas; C Hicks; S M Hammer; D Cooper; M Johnson; S Tortell; A Cutrell; D Thorborn; R Isaacs; S Hetherington; H Steel; W Spreen
Journal: JAMA Date: 2001-03-07 Impact factor: 56.272

3. Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.

Authors: Wei Zhao; Massimo Cella; Oscar Della Pasqua; David Burger; Evelyne Jacqz-Aigrain
Journal: Br J Clin Pharmacol Date: 2012-04 Impact factor: 4.335

4. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.

Authors: Graeme J Moyle; Edwin DeJesus; Pedro Cahn; Steve A Castillo; Henry Zhao; David N Gordon; Charles Craig; Trevor R Scott
Journal: J Acquir Immune Defic Syndr Date: 2005-04-01 Impact factor: 3.731

5. Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects.

Authors: S Weller; K M Radomski; Y Lou; D S Stein
Journal: Antimicrob Agents Chemother Date: 2000-08 Impact factor: 5.191

6. Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women.

Authors: Hélène Chappuy; Jean-Marc Tréluyer; Vincent Jullien; Jérôme Dimet; Elisabeth Rey; Maria Fouché; Ghislaine Firtion; Gérard Pons; Laurent Mandelbrot
Journal: Antimicrob Agents Chemother Date: 2004-11 Impact factor: 5.191

Population pharmacokinetics of abacavir in pregnant women.

1. Ways to fit a PK model with some data below the quantification limit.

2. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.

3. Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.

4. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.

5. Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects.

6. Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women.

7. Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.

Review 8. Pharmacokinetics of antiretrovirals in pregnant women.

9. Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children.

10. Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.

1. Pregnancy-induced changes in the pharmacokinetics of caffeine and its metabolites.